N. Galldiks, N. L. Albert, M. Sommerauer, A. L. Grosu, U. Ganswindt et al., PET imaging in patients with meningioma-report of the RANO/PET Group, Neuro Oncol, vol.19, pp.1576-87, 2017.

R. Goldbrunner, G. Minniti, M. Preusser, M. D. Jenkinson, K. Sallabanda et al., EANO guidelines for the diagnosis and treatment of meningiomas, Lancet Oncol, vol.17, issue.16, pp.30321-30328, 2016.

T. Kaley, I. Barani, M. Chamberlain, M. Mcdermott, K. Panageas et al., Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: a RANO review, Neuro Oncol, vol.16, pp.829-869, 2014.

J. Strosberg, G. El-haddad, E. Wolin, A. Hendifar, J. Yao et al., Phase 3 Trial of, N Engl J Med, vol.376, pp.125-160, 2017.

T. Graillon, D. Romano, C. Defilles, A. Saveanu, A. Mohamed et al.,

, Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review, J Neurosurg, vol.127, pp.660-669, 2017.

M. L. Soto-montenegro, S. Peña-zalbidea, J. M. Mateos-pérez, M. Oteo, E. Romero et al., Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice, PLoS One, vol.9, 2014.

M. Sommerauer, J. K. Burkhardt, K. Frontzek, E. Rushing, A. Buck et al., 68GalliumDOTATATE PET in meningioma: A reliable predictor of tumor growth rate?, Neuro Oncol, vol.18, pp.1021-1028, 2016.

K. Gerster-gilliéron, F. Forrer, H. Maecke, J. Mueller-brand, A. Merlo et al., 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas, J Nucl Med, vol.56, pp.1748-51, 2015.

N. Marincek, P. Radojewski, R. A. Dumont, P. Brunner, J. Müller-brand et al., Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial, J Nucl Med, vol.56, pp.171-177, 2015.

M. Bartolomei, L. Bodei, D. Cicco, C. Grana, C. M. Cremonesi et al., Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma, Eur J Nucl Med Mol Imaging, vol.36, pp.1407-1423, 2009.
DOI : 10.1007/s00259-009-1115-z

A. Sabet, H. Ahmadzadehfar, U. Herrlinger, W. Wilinek, H. J. Biersack et al., Successful radiopeptide targeting of metastatic anaplastic meningioma: case report, Radiat Oncol, vol.6, p.94, 2011.
DOI : 10.1186/1748-717x-6-94
URL : https://ro-journal.biomedcentral.com/track/pdf/10.1186/1748-717X-6-94

K. Seystahl, V. Stoecklein, U. Schüller, E. Rushing, G. Nicolas et al., Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma, Neuro Oncol, vol.18, pp.1599-606, 2006.

M. C. Kreissl, H. Hänscheid, M. Löhr, F. A. Verburg, M. Schiller et al., Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma, Radiat Oncol, vol.7, p.99, 2012.

P. Backhaus, S. Huss, V. Kösek, M. Weckesser, and K. Rahbar, Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy, Clin Nucl Med, vol.43, pp.184-189, 2018.

M. Cremonesi, M. E. Ferrari, L. Bodei, C. Chiesa, A. Sarnelli et al., Correlation of dose with toxicity and tumour response to, Eur J Nucl Med Mol Imaging, 2018.

M. Sandström, U. Garske-román, D. Granberg, S. Johansson, C. Widström et al., Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment, J Nucl Med, vol.54, pp.33-41, 2013.

A. Sundlöv, K. Sjögreen-gleisner, J. Svensson, M. Ljungberg, T. Olsson et al.,

. Individualised, Eur J Nucl Med Mol Imaging, vol.44, pp.1480-1489, 2017.

M. Del-prete, F. A. Buteau, J. M. Beauregard, and . Personalized, Eur J Nucl Med Mol Imaging, vol.44, 2017.